延迟化疗引起的恶心 - 在常规瘤学实践中进行的一项护士领导的国际观察研究 (CINrate)
Ramona Engst1, Agnes Glaus2, Ulrike Moessner3
1School of Health, OST Eastern Switzerland University of Applied Sciences, St.Gallen, Switzerland.
SAGE open nursing
|December 8, 2025
概括
延迟化疗诱导的恶心 (dCIN) 影响了近19%的接受低 emetogenic 化疗 (LEC) 的患者. 这凸显了需要更好的症状管理策略,超越目前癌症患者的风险分类.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 患者的生活质量.
背景情况:
- 化疗诱导的恶心和吐 (CINV) 显著影响患者的生活质量和治疗坚持.
- 延迟CINV (dCIN) 通常与中度/高排泄性化疗相关,但可以在低 (LEC) 和最小 (MinEC) 疗程中发生.
- 关于dCIN发生的现实数据,特别是LEC和MinEC,对于优化支持性护理至关重要.
研究的目的:
- 评估在接受全身抗瘤治疗的患者中延迟化疗诱导的恶心 (dCIN) 的发生率和特征.
- 专门评估在接受低 (LEC) 和最小 emetogenic 化疗 (MinEC) 的患者中dCIN发生的情况.
- 在现实临床环境中识别与dCIN相关的风险因素.
主要方法:
- 未来,多中心,国际,横截面研究.
- 包括接受全身抗瘤治疗的成人瘤门诊患者.
- 延迟CINV强度每天使用0-100视觉模拟尺度 (VAS) 连续五天进行自我评估.
主要成果:
- 晚期化疗诱导的恶心 (dCIN) 发生在接受低 emetogenic 化疗 (LEC) 的18.5%的患者和接受最小 emetogenic 化疗 (MinEC) 的3%的患者中.
- 吐是不常见的 (1.7%).
- 对于dCIN的独立风险因素包括年轻的年龄和胃肠道瘤;在最终模型中,排泄性,恐惧和先前吐并不是显著的预测因素.
结论:
- 在临床实践中,接受低发泄性化疗 (LEC) 的大量患者经历了延迟化疗诱导的恶心 (dCIN).
- 目前的发性风险分类可能无法完全捕捉dCIN的风险.
- 对于经历dCIN的患者来说,无论化疗的 emetogenicity,都需要改善症状管理和量身定制的干预措施.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
524
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
524
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
576
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
576
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
653
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
653
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
790
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
790
Nursing Ethical Principles II
2.0K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
2.0K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

